Valuation: AtheroNova Inc.

Market Cap 24.67L 21.51L 20.31L 18.44L 34.55L 24Cr 34.7L 2.43Cr 93.88L 12Cr 92.66L 90.6L 39Cr P/E 2012
-4.89x
P/E 2013 -1.93x
Enterprise Value 29.54L 25.76L 24.32L 22.08L 41.38L 28Cr 41.55L 2.91Cr 1.12Cr 14Cr 1.11Cr 1.08Cr 46Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Director TitleAgeSince
Director/Board Member 54 03/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.69T
+0.11%+2.71%+0.33%+28.59% 4.63TCr
-1.12%+1.78%+40.07%+27.26% 4.39TCr
-3.04%-6.29%+322.27%+517.36% 4.09TCr
-0.74%+1.25%+2.32%+67.94% 3.99TCr
-0.50%+0.67%+11.79%+40.51% 2.95TCr
-0.46%+4.22%+21.99%+124.21% 1.71TCr
-0.97%-10.17% - - 1.55TCr
-0.57%+8.12%+22.15%+38.93% 1.52TCr
-3.14%+31.91%-10.60% - 1.4TCr
Average -0.89%+3.39%+51.29%+120.69% 2.62TCr
Weighted average by Cap. -1.02%+1.87%+64.69%+130.23%

Financials

2012 2013
Net sales - -
Net income -26.36L -22.98L -21.7L -19.71L -36.92L -25Cr -37.07L -2.6Cr -1Cr -13Cr -99L -96.81L -41Cr -78.15L -68.14L -64.34L -58.43L -1.09Cr -75Cr -1.1Cr -7.71Cr -2.97Cr -38Cr -2.94Cr -2.87Cr -122.67Cr
Net Debt -23.83L -20.78L -19.62L -17.82L -33.39L -23Cr -33.53L -2.35Cr -90.71L -12Cr -89.53L -87.54L -37Cr 5L 4L 4L 4L 7L 4.67Cr 7L 48.04L 18.54L 2.38Cr 18.3L 17.89L 7.65Cr
Logo AtheroNova Inc.
AtheroNova Inc is a United States-based biopharmaceutical company. The Company through its subsidiary is focused on the research and development of compounds to regress atherosclerotic plaque and improve lipid profiles in humans. The Company develops various applications for its compounds to be used for the treatment of atherosclerosis. The Company's development products include AHRO-001 and AHRO-002. The Company's pipeline candidates include applications for the treatment of localized reduction of subcutaneous fat deposits through transdermal application, obesity, hypertension, diabetes and Peripheral Artery Disease (PAD). The Company's lead compound is AHRO-001. Through the process of reverse cholesterol transport, the compound is designed to dissolve plaque within the walls of the arteries and removes it from the body through natural metabolic processes. AHRO-001 and AHRO-002 are orally administered compounds.
Employees
-
  1. Stock Market
  2. Stocks
  3. AHROQ Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!